

Keisuke Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5422259/publications.pdf>

Version: 2024-02-01

65
papers

3,205
citations

147566

31
h-index

155451

55
g-index

66
all docs

66
docs citations

66
times ranked

5249
citing authors

#	ARTICLE	IF	CITATIONS
1	MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. <i>Gastroenterology</i> , 2022, 162, 1272-1287.e16.	0.6	16
2	Targeting autophagy as a therapeutic strategy against pancreatic cancer. <i>Journal of Gastroenterology</i> , 2022, 57, 603-618.	2.3	12
3	Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. <i>Cell Metabolism</i> , 2021, 33, 199-210.e8.	7.2	42
4	Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 99.	2.7	19
5	Autophagy is required for proper cysteine homeostasis in pancreatic cancer through regulation of SLC7A11. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
6	The polar oxy-metabolome reveals the 4-hydroxymandelate CoQ10 synthesis pathway. <i>Nature</i> , 2021, 597, 420-425.	13.7	22
7	Abstract PO-067: A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. , 2021, , .		0
8	Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 21194.	1.6	14
9	Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. <i>Cell</i> , 2020, 183, 1202-1218.e25.	13.5	128
10	Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 695-705.	1.0	9
11	5-Aminolevulinic acid-mediated photodynamic activity in patient-derived cholangiocarcinoma organoids. <i>Surgical Oncology</i> , 2020, 35, 484-490.	0.8	8
12	Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 1018-1037.	7.7	104
13	Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer. <i>Autophagy</i> , 2020, 16, 1524-1525.	4.3	49
14	Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. <i>Nature</i> , 2020, 581, 100-105.	13.7	628
15	Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation. <i>Scientific Reports</i> , 2019, 9, 18859.	1.6	18
16	Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. <i>Cancer Science</i> , 2018, 109, 3602-3610.	1.7	17
17	Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation. <i>Oncogene</i> , 2017, 36, 6262-6271.	2.6	38
18	Survey on Preclinical Methods to Assess Collateral Thermal Damage to Tissues Caused by Surgical Devices. <i>Journal of Japan Society of Computer Aided Surgery</i> , 2017, 19, 63-73.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. <i>Oncogenesis</i> , 2016, 5, e277-e277.	2.1	27
20	A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. <i>Scientific Reports</i> , 2016, 6, 23899.	1.6	60
21	Quantitation of circulating satellite RNAs in pancreatic cancer patients. <i>JCI Insight</i> , 2016, 1, e86646.	2.3	34
22	Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 61469-61484.	0.8	64
23	No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer. <i>Anticancer Research</i> , 2016, 36, 4965-4970.	0.5	5
24	Epigenome modifying enzymes regulate development and progression of pancreatic cancers. <i>Suizo</i> , 2016, 31, 69-75.	0.1	0
25	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 933-939.	1.2	21
26	Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP β . <i>Carcinogenesis</i> , 2014, 35, 2404-2414.	1.3	83
27	Metallic stent with high axial force as a risk factor for cholecystitis in distal malignant biliary obstruction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1557-1562.	1.4	65
28	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 911-915.	1.1	7
29	Slow Pull Versus Suction in Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Solid Masses. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1578-1585.	1.1	152
30	Disease-Specific Mortality Among Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 486-491.	2.4	16
31	A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 290-290.	0.8	0
32	Associations between K-ras mutation, smoking, and prognosis of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 298-298.	0.8	0
33	The results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial. <i>Journal of Gastroenterology</i> , 2013, 48, 982-988.	2.3	13
34	Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. <i>Journal of Gastroenterology</i> , 2013, 48, 238-246.	2.3	40
35	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1291-1297.	1.1	16
36	Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. <i>Pancreatology</i> , 2013, 13, 285-289.	0.5	20

#	ARTICLE	IF	CITATIONS
37	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. <i>Investigational New Drugs</i> , 2013, 31, 1294-1299.	1.2	45
38	Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. <i>Carcinogenesis</i> , 2013, 34, 2380-2388.	1.3	40
39	Risk for Mortality From Causes Other Than Pancreatic Cancer in Patients With Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Pancreas</i> , 2013, 42, 687-691.	0.5	33
40	Erlotinib Prolongs Survival in Pancreatic Cancer by Blocking Gemcitabine-Induced MAPK Signals. <i>Cancer Research</i> , 2013, 73, 2221-2234.	0.4	47
41	A Novel, Fully Covered Laser-Cut Nitinol Stent with Antimigration Properties for Nonresectable Distal Malignant Biliary Obstruction: A Multicenter Feasibility Study. <i>Gut and Liver</i> , 2013, 7, 725-730.	1.4	33
42	Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. <i>Cancer Science</i> , 2012, 103, 670-676.	1.7	241
43	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. <i>Cancer Science</i> , 2012, 103, 1489-1492.	1.7	36
44	Clinical utility of single-operator cholangiopancreatography using a SpyGlass probe through an endoscopic retrograde cholangiopancreatography catheter. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1371-1376.	1.4	16
45	ENDOSCOPIC REMOVAL OF A SPONTANEOUSLY FRACTURED BILIARY UNCOVERED SELF-EXPANDABLE METAL STENT. <i>Digestive Endoscopy</i> , 2012, 24, 182-184.	1.3	5
46	Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. <i>Investigational New Drugs</i> , 2012, 30, 708-713.	1.2	72
47	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. <i>Journal of Hepatology</i> , 2011, 55, 1400-1408.	1.8	57
48	Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. <i>Investigational New Drugs</i> , 2011, 29, 1488-1493.	1.2	33
49	Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 463-467.	1.3	63
50	A large volume of visceral adipose tissue leads to severe acute pancreatitis. <i>Journal of Gastroenterology</i> , 2011, 46, 1213-1218.	2.3	79
51	Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. <i>Journal of Gastroenterology</i> , 2011, 46, 1411-1417.	2.3	36
52	Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 847-853.	1.1	26
53	Noncalcified pancreatic stone treated with electrohydraulic lithotripsy using SpyGlass pancreatoscopy. <i>Endoscopy</i> , 2011, 43, E272-E272.	1.0	5
54	Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer. <i>Oncology</i> , 2011, 80, 97-101.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. <i>Gut</i> , 2011, 60, 1249-1253.	6.1	60
56	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. <i>World Journal of Clinical Oncology</i> , 2011, 2, 158.	0.9	22
57	Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer. <i>Pancreas</i> , 2010, 39, 989-993.	0.5	27
58	Bezafibrate for the treatment of primary sclerosing cholangitis. <i>Journal of Gastroenterology</i> , 2010, 45, 758-762.	2.3	41
59	Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. <i>British Journal of Cancer</i> , 2010, 103, 1644-1648.	2.9	150
60	Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 85-90.	0.5	69
61	Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 1042-1046.	1.0	61
62	A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer. <i>Oncology</i> , 2009, 77, 300-303.	0.9	28
63	NOTES and endoscopic pancreatic necrosectomy for the GI endoscopist. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2009, 16, 270-273.	2.0	12
64	Diagnostic utility of biopsy specimens for autoimmune pancreatitis. <i>Journal of Gastroenterology</i> , 2009, 44, 765-773.	2.3	53
65	Transluminal endoscopic necrosectomy for infected pancreatic necrosis. <i>Progress of Digestive Endoscopy</i> , 2009, 75, 116-117.	0.0	0